Somewhat Favorable Media Coverage Somewhat Unlikely to Impact MiMedx Group (MDXG) Stock Price
Media stories about MiMedx Group (NASDAQ:MDXG) have been trending somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. MiMedx Group earned a news sentiment score of 0.08 on Accern’s scale. Accern also assigned news coverage about the medical equipment provider an impact score of 43.4359068348942 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the media stories that may have impacted Accern Sentiment’s rankings:
- Average True Range (ATR) under Consideration – MiMedx Group, Inc., (NASDAQ: MDXG) – Stock Watch (stocksnewstimes.com)
- MiMedx down 5% on new Viceroy report of misconduct – Seeking Alpha (seekingalpha.com)
- MiMedx Provides Update On Its Reimbursement Coverage (finance.yahoo.com)
- MiMedx to Present at the 29th Annual Piper Jaffray Healthcare Conference (finance.yahoo.com)
- Stocks Active Momentum: MiMedx Group, Inc. (NASDAQ:MDXG) a Medical Appliances & Equipment Company – The Stock Street (press release) (thestreetpoint.com)
Shares of MiMedx Group (NASDAQ:MDXG) traded down $0.09 during trading on Wednesday, reaching $10.87. 1,391,024 shares of the company’s stock traded hands, compared to its average volume of 1,734,327. MiMedx Group has a 12-month low of $7.64 and a 12-month high of $17.47. The company has a market capitalization of $1,210.00, a PE ratio of 52.67, a PEG ratio of 2.63 and a beta of 0.91.
MiMedx Group (NASDAQ:MDXG) last issued its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.08 EPS for the quarter, hitting the consensus estimate of $0.08. The firm had revenue of $84.60 million for the quarter, compared to analysts’ expectations of $84.60 million. MiMedx Group had a net margin of 11.64% and a return on equity of 17.49%. MiMedx Group’s revenue for the quarter was up 31.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.06 earnings per share. equities analysts anticipate that MiMedx Group will post 0.24 EPS for the current fiscal year.
MiMedx Group declared that its Board of Directors has authorized a share buyback program on Wednesday, July 26th that authorizes the company to repurchase $14.00 million in outstanding shares. This repurchase authorization authorizes the medical equipment provider to buy up to 0.9% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company’s management believes its stock is undervalued.
Several brokerages have commented on MDXG. BidaskClub upgraded shares of MiMedx Group from a “hold” rating to a “buy” rating in a research report on Thursday, August 10th. Needham & Company LLC reiterated a “buy” rating and issued a $21.00 price target on shares of MiMedx Group in a research report on Tuesday, November 14th. Piper Jaffray Companies reiterated a “buy” rating and issued a $18.00 price target on shares of MiMedx Group in a research report on Sunday, August 20th. Lake Street Capital boosted their price target on shares of MiMedx Group from $16.00 to $18.00 and gave the stock a “buy” rating in a research report on Friday, July 28th. Finally, Zacks Investment Research cut shares of MiMedx Group from a “hold” rating to a “sell” rating in a research report on Wednesday, October 4th. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $15.40.
COPYRIGHT VIOLATION WARNING: This news story was first published by Daily Political and is the property of of Daily Political. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States & international copyright and trademark law. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/11/22/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-mimedx-group-mdxg-stock-price.html.
About MiMedx Group
MiMedx Group, Inc is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company’s Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories.
Receive News & Ratings for MiMedx Group Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group Inc and related companies with MarketBeat.com's FREE daily email newsletter.